TEM Tempus AI, Inc.
Company Analysis
Latest News
🟢 Tempus AI, Inc. is trading 9.6% up today on technical bounce after recent selloff
Tempus AI, Inc. is trading 9.6% up at $52.05, rebounding sharply after several days of heavy selling and profit-taking. • The move suggests a technical bounce...
🔴 Tempus AI, Inc. is trading 4.8% down today on profit-taking after pathology consortium launch
Tempus AI, Inc. is trading 4.8% down at $47.23 as investors take profits following the announcement of a new digital pathology open-source consortium. • The...
🔴 Tempus AI, Inc. is trading 4.6% down today despite announcing new digital pathology consortium with Yale and Memorial Sloan Kettering
Tempus AI, Inc. is trading 4.6% down at $47.33 today, a move that comes despite the company announcing a significant new initiative. • Tempus has launched a...
🔴 Tempus AI, Inc. is trading 5.5% down today on profit-taking following a sharp post-earnings rally
Tempus AI, Inc. is trading at $49.89, down 5.5% today as the stock pulls back from a significant rally fueled by strong Q1 results and bullish analyst...
🟢 Tempus AI, Inc. is trading 5.2% up today after Needham reiterates Buy rating and new cancer test launch
Tempus AI, Inc. is trading 5.2% up now at $53.08 following a positive analyst update and the introduction of a new oncology product. • Needham today...
Tempus AI to Launch xH Test, Finding 40% More Cancer Targets
Tempus AI will soon launch xH, its first whole-genome sequencing (WGS) assay for clinical use. The test identifies actionable cancer targets in blood and bone...
Tempus AI Unveils Next-Generation 'Lens' Platform to Accelerate Oncology Drug Development
Tempus AI has launched the next generation of its Lens platform, an agentic AI system designed to accelerate oncology drug development and research. This...
Tempus AI Launches 'Preview' to Speed Up Cancer Diagnostics
Tempus AI launched "Preview," an AI-powered application for precision oncology. The tool shortens the time between ordering diagnostic tests and receiving...
Tempus AI Outperforms Clinical Standards, Predicting Cancer Survival with New Model
Tempus AI (NASDAQ: TEM) announced initial results from its multimodal oncology foundation model at the 2026 American Society of Clinical Oncology (ASCO) Annual...
Tempus AI Expands 'Next' Platform for Real-Time Cancer Care Intelligence
Tempus AI expanded its AI-enabled 'Next' platform to deliver real-time clinical intelligence for oncology. The update introduces capabilities for six new...
Tempus AI Upgrades Tempus Hub With Agentic AI, Automating Oncology Workflows
Tempus AI integrated a next-generation agentic AI architecture into its Tempus Hub physician platform. The upgrade provides oncologists with an agent-first...
🟢 TEM surges 4.1% after announcing dozens of studies to be presented at major oncology conference
TEM is trading at $48.07 (+4.1%) after the company announced significant upcoming data presentations. • Tempus announced that 37 abstracts have been accepted...
Tempus AI Launches ArteraAI Prostate Test to Predict Patient Mortality
Tempus AI launched the ArteraAI Prostate Test for patients with metastatic hormone-sensitive prostate cancer. This release marks the first time Tempus has...
🟢 TEM is trading 5.4% up today after announcing validation wins for its Cardiac AI diagnostics platform
TEM is trading 5.4% up today at $45.98 after the company announced significant validation wins for its Cardiac AI diagnostics platform across regulatory and...
🟢 TEM is trading 4.2% up today on technical rebound after recent slide
TEM is trading up 4.2% at $45.44 on a technical rebound and dip-buying interest following a week of steady declines. • The move comes despite a lack of fresh...
🟢 TEM is trading 4% up today, rebounding from last week's slide
TEM is trading 4% up today at $45.38, rebounding from last week’s steady slide and a modest loss on May 18. • There are currently no fresh company-specific...
Tempus AI Expands Bristol Myers Squibb Deal, Optimizing Clinical Trials
Tempus AI expanded its strategic collaboration with Bristol Myers Squibb to improve clinical development success rates. The partnership leverages Tempus’ AI...
Tempus AI Completes $460M Offering of 0.00% Convertible Senior Notes Due 2032
Tempus AI, Inc. has completed a private offering of $460 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2032. This amount includes...
Tempus AI Completes $400 Million Convertible Senior Notes Offering
Tempus AI, Inc. closed an offering of $400 million in convertible senior notes due 2032. The company increased the total from $350 million, reflecting strong...
Tempus AI Closes $400M Upsized Debt Offering to Repay Loans
Tempus AI finalized its upsized offering of $400 million in 0.00% Convertible Senior Notes due 2032. The offering increased from the initial $350 million...